<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1173</ReferenceId>
        <DateLastUpdated>2018-10-16-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15852016</PubmedId>
            <Abstract>Neutralization of West Nile virus (WNV) in vivo correlates with the development of an antibody response against the viral envelope (E) protein. Using random mutagenesis and yeast surface display, we defined individual contact residues of 14 newly generated monoclonal antibodies against domain III of the WNV E protein. Monoclonal antibodies that strongly neutralized WNV localized to a surface patch on the lateral face of domain III. Convalescent antibodies from individuals who had recovered from WNV infection also detected this epitope. One monoclonal antibody, E16, neutralized 10 different strains in vitro, and showed therapeutic efficacy in mice, even when administered as a single dose 5 d after infection. A humanized version of E16 was generated that retained antigen specificity, avidity and neutralizing activity. In postexposure therapeutic trials in mice, a single dose of humanized E16 protected mice against WNV-induced mortality, and may therefore be a viable treatment option against WNV infection in humans.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>522-30</ArticlePages>
            <ArticleTitle>Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Oliphant</LastName>
                    <ForeName>Theodore</ForeName>
                </Author>
                <Author>
                    <LastName>Engle</LastName>
                    <ForeName>Michael</ForeName>
                </Author>
                <Author>
                    <LastName>Nybakken</LastName>
                    <ForeName>Grant E</ForeName>
                </Author>
                <Author>
                    <LastName>Doane</LastName>
                    <ForeName>Chris</ForeName>
                </Author>
                <Author>
                    <LastName>Johnson</LastName>
                    <ForeName>Syd</ForeName>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Ling</ForeName>
                </Author>
                <Author>
                    <LastName>Gorlatov</LastName>
                    <ForeName>Sergey</ForeName>
                </Author>
                <Author>
                    <LastName>Mehlhop</LastName>
                    <ForeName>Erin</ForeName>
                </Author>
                <Author>
                    <LastName>Marri</LastName>
                    <ForeName>Anantha</ForeName>
                </Author>
                <Author>
                    <LastName>Chung</LastName>
                    <ForeName>Kyung Min</ForeName>
                </Author>
                <Author>
                    <LastName>Ebel</LastName>
                    <ForeName>Gregory D</ForeName>
                </Author>
                <Author>
                    <LastName>Kramer</LastName>
                    <ForeName>Laura D</ForeName>
                </Author>
                <Author>
                    <LastName>Fremont</LastName>
                    <ForeName>Daved H</ForeName>
                </Author>
                <Author>
                    <LastName>Diamond</LastName>
                    <ForeName>Michael S</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Molecular Microbiology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8051, St. Louis, Missouri 63110, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;DNA Primers;Viral Envelope Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(immunology); Cloning, Molecular; DNA Primers; Enzyme-Linked Immunosorbent Assay; Epitope Mapping; Humans; Immunotherapy; Mice; Mice, Inbred C57BL; Mutagenesis; Neutralization Tests; Plasmids(genetics); Viral Envelope Proteins(immunology; metabolism); West Nile Fever(immunology; therapy); West Nile virus(immunology); Yeasts</ArticleMeshHeadingsList>
            <Journal>
                <Volume>11</Volume>
                <Issue>5</Issue>
                <Title>Nature medicine</Title>
                <Issn>1078-8956</Issn>
                <MedlineTa>Nat Med</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>S592, K593, T616, T618</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AAA48498.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000447</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 2</LocationOfData>
                <EpitopeId>187599</EpitopeId>
                <ReferenceRegion>S306, K307, T330, T332</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>These residues are located on adjacent loops of Domain III (aa296-415) of source antigen ectodomain, forming a continuous patch on the solvent-exposed surface.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Supplementary data</LocationOfData>
                        <BCellId>16638</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAA48498.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000447</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>E protein ectodomain</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <DoseSchedule>2 doses of 25 micrograms, 3 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Source protein ectodomain was expressed as a recombinant protein, including the signal sequence from viral polyprotein and aas 1-415 from E-protein along with a C-terminal His tag, in Hi-5 insect cells. Immune splenocytes from high titer responder animals were used for hybridoma production by fusion with P3X63Ag8.653 myeloma cells. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Neutralizing mAbs E16 and E24, shown to recognize this epitope, are able to inhibit infectivity of WNV to BHK21 fibroblasts, J774.2 mouse macrophages and SW13 human adrenal carcinoma cells, implying the inhibition is not cell specific. E16 is also able to inhibit infectivity of Vero cells of all the WNV strains assayed, but not of closely related Japanese and St. Louis encephalitis viruses. These mAbs are shown to reduce mortality when injected 2 days after source species infection, in a dose dependent manner. Even if injected 4  and 5 days after infection, these mAbs promote enhanced survival.  E16 is also shown to be able to significantly reduce the viral load in the CNS at day 9 post infection when injected as a single dose of 2 mg at day 5 post infection.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>E16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2b</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>West nile virus</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000447</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2 and table I</LocationOfData>
                        <BCellId>16637</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAA48498.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000447</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>E protein ectodomain</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <DoseSchedule>2 doses of 25 micrograms, 3 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Source protein ectodomain was expressed as a recombinant protein, including the signal sequence from viral polyprotein and aas 1-415 from E-protein along with a C-terminal His tag, in Hi-5 insect cells. Immune splenocytes from high titer responder animals were used for hybridoma production by fusion with P3X63Ag8.653 myeloma cells. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Wild type DIII domain expressed on the surface of yeast cells is recognized by 10 mAbs showing strong neutralizing activity, while mutant DIII domains harboring mutations at epitopic residues are not recognized. Mutation at residue K307 abolishes recognition by all of the 10 mAbs, while mutations at T330 and T332 abolish recognition by 9 of the mAbs and mutation at S306 abolishes recognition of 5 of these mAbs. 6 of these mAbs are of IgG2a, 2 are of IgG2b, and 2 are of IgG1 isotypes.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>E34, E16, E24 and several others</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>DIII</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLKGTTYGVCSKAFKFARTPADTGHGTVVLELQYTGTDGPCKVPISSVASLNDLTPVGRLVTVNPFVSVATANSKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGKAFTTTLRGA</LinearSequence>
                                        <SourceMolecule>
                                            <GenBankId>AAA48498.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000447</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4C</LocationOfData>
                        <BCellId>16645</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAA48498.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000447</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>E protein ectodomain</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <DoseSchedule>2 doses of 25 micrograms, 3 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Source protein ectodomain was expressed as a recombinant protein, including the signal sequence from viral polyprotein and aas 1-415 from E-protein along with a C-terminal His tag, in Hi-5 insect cells. Immune splenocytes from high titer responder animals were used for hybridoma production by fusion with P3X63Ag8.653 myeloma cells. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>45</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.4</QuantitativeMeasurement>
                            <AssayComments>Neutralizing mAb E16, shown to recognize this epitope, recognizes recombinant DIII domain of source protein with a KD of 3.4 nM.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>E16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2b</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>DIII</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLKGTTYGVCSKAFKFARTPADTGHGTVVLELQYTGTDGPCKVPISSVASLNDLTPVGRLVTVNPFVSVATANSKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGKAFTTTLRGA</LinearSequence>
                                        <SourceMolecule>
                                            <GenBankId>AAA48498.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000447</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4D</LocationOfData>
                        <BCellId>17595</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAA48498.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000447</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>E protein ectodomain</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <DoseSchedule>2 doses of 25 micrograms, 3 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Source protein ectodomain was expressed as a recombinant protein, including the signal sequence from viral polyprotein and aas 1-415 from E-protein along with a C-terminal His tag, in Hi-5 insect cells. Immune splenocytes from high titer responder animals were used for hybridoma production by fusion with P3X63Ag8.653 myeloma cells. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Humanized version of E16 (i.e., with CDR regions grafted onto a human Ab backbone) and chimeric (i.e., with mouse variable and human constant regions), are as effective as original mouse mAb E16 in neutralizing viral infectivity of BHK-21 fibroblasts. They also provide protection when injected 2 days after source species infection. The protection afforded by the chimeric version of E16 is partly dependent on complement activation and dependent on Fc-receptor engagement. The protection afforded by the humanized version  is improved by back mutation of framework residues 49 of VL and 71of VH, which were shown to improve the binding affinity to DIII.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Humanized E16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>West nile virus</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000447</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4C</LocationOfData>
                        <BCellId>17594</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAA48498.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000447</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>E protein ectodomain</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <DoseSchedule>2 doses of 25 micrograms, 3 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Source protein ectodomain was expressed as a recombinant protein, including the signal sequence from viral polyprotein and aas 1-415 from E-protein along with a C-terminal His tag, in Hi-5 insect cells. Immune splenocytes from high titer responder animals were used for hybridoma production by fusion with P3X63Ag8.653 myeloma cells. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>45</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>7.1</QuantitativeMeasurement>
                            <AssayComments>Humanized (i.e., with CDR regions grafted onto a human Ab backbone) and chimeric (i.e., with mouse variable and human constant regions) versions of neutralizing murine mAb E16 (shown to recognize recombinant DIII domain of source protein with a KD of 3.4 nM), are also able  to bind DIII, with affinities of 21 and 10.8 nM respectively. Affinity of the humanized version  is shown to be improved by back mutation of framework residues 49 of VL and 71of VH, up to 7.1 nM (Humanized E16.3).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Humanized E16.3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>DIII</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLKGTTYGVCSKAFKFARTPADTGHGTVVLELQYTGTDGPCKVPISSVASLNDLTPVGRLVTVNPFVSVATANSKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGKAFTTTLRGA</LinearSequence>
                                        <SourceMolecule>
                                            <GenBankId>AAA48498.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000447</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>K596, N680</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AAA48498.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000447</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 2</LocationOfData>
                <EpitopeId>187598</EpitopeId>
                <ReferenceRegion>K310, N394</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>These residues are located on the solvent-exposed surface of Domain III (aa296-415) of source antigen ectodomain.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2 and table I</LocationOfData>
                        <BCellId>16647</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAA48498.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000447</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>E protein ectodomain</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <DoseSchedule>2 doses of 25 micrograms, 3 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Source protein ectodomain was expressed as a recombinant protein, including the signal sequence from viral polyprotein and aas 1-415 from E-protein along with a C-terminal His tag, in Hi-5 insect cells. Immune splenocytes from high titer responder animals were used for hybridoma production by fusion with P3X63Ag8.653 myeloma cells. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Wild type DIII domain expressed on the surface of yeast cells is recognized by a mAb showing weak neutralizing activity, while mutant DIII domains harboring mutations at epitopic residues are not recognized.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>E1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>DIII</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLKGTTYGVCSKAFKFARTPADTGHGTVVLELQYTGTDGPCKVPISSVASLNDLTPVGRLVTVNPFVSVATANSKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGKAFTTTLRGA</LinearSequence>
                                        <StartingPosition>582</StartingPosition>
                                        <EndingPosition>701</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAA48498.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000447</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

